<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Spin-off Portfolio &#8211; Partners Medical International</title>
	<atom:link href="https://davekuhar.github.io/partners-med-static/portfolio-type/spin-off-portfolio/feed" rel="self" type="application/rss+xml" />
	<link>https://davekuhar.github.io/partners-med-static/</link>
	<description></description>
	<lastBuildDate>Tue, 22 Dec 2015 17:14:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.8.1</generator>

<image>
	<url>https://davekuhar.github.io/partners-med-static/wp-content/uploads/2016/11/cropped-p-favicon-32x32.png</url>
	<title>Spin-off Portfolio &#8211; Partners Medical International</title>
	<link>https://davekuhar.github.io/partners-med-static/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Selecta Biosciences, Inc.</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/selecta-biosciences-inc</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/selecta-biosciences-inc</guid>

					<description><![CDATA[<p>Selecta Biosciences, Inc.is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. Selecta’s synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Selecta Biosciences, Inc.is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP<img src="https://s.w.org/images/core/emoji/13.1.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />) technology. Selecta’s synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Symbiotix Biotherapies, Inc.</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/symbiotix-biotherapies-inc</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/symbiotix-biotherapies-inc</guid>

					<description><![CDATA[<p>Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. The company&#8217;s lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/symbiotix-biotherapies-inc">Symbiotix Biotherapies, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. The company&#8217;s lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/symbiotix-biotherapies-inc">Symbiotix Biotherapies, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>T2 Biosystems</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/t2-biosystems</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/t2-biosystems</guid>

					<description><![CDATA[<p>T2 Biosystems T2 Biosystems (NASDAQ: TTOO) is a biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/t2-biosystems">T2 Biosystems</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>T2 Biosystems T2 Biosystems (NASDAQ: TTOO) is a biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/t2-biosystems">T2 Biosystems</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Verinata Health, Inc.</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/verinata-health-inc</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/verinata-health-inc</guid>

					<description><![CDATA[<p>Verinata Health, Inc. (acquired by Illumina, Inc.) developed non-invasive tests for the early identification of fetal chromosomal abnormalities.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/verinata-health-inc">Verinata Health, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Verinata Health, Inc. (acquired by Illumina, Inc.) developed non-invasive tests for the early identification of fetal chromosomal abnormalities.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/verinata-health-inc">Verinata Health, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>XTuit Pharmaceuticals</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/xtuit-pharmaceuticals</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/xtuit-pharmaceuticals</guid>

					<description><![CDATA[<p>XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/xtuit-pharmaceuticals">XTuit Pharmaceuticals</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/xtuit-pharmaceuticals">XTuit Pharmaceuticals</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ZELTIQ</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/zeltiq</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/zeltiq</guid>

					<description><![CDATA[<p>ZELTIQ™(NASDAQ: ZLTQ) is medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat. The device is cleared by the FDA in the United States for various applications related to skin cooling during dermatologic treatments, with a pending application for non-invasive body fat reduction. Based on a method to kill&#8230;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/zeltiq">ZELTIQ</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>ZELTIQ<img src="https://s.w.org/images/core/emoji/13.1.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />(NASDAQ: ZLTQ) is medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat. The device is cleared by the FDA in the United States for various applications related to skin cooling during dermatologic treatments, with a pending application for non-invasive body fat reduction. Based on a method to kill only fat cells, the company uses a novel method named Cryolipolysis<img src="https://s.w.org/images/core/emoji/13.1.0/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> (the use of precisely controlled cooling to remove fat).</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/zeltiq">ZELTIQ</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>BIND Biosciences</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/bind-biosciences</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:16 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/bind-biosciences</guid>

					<description><![CDATA[<p>BIND Biosciences (NASDAQ: BIND) is a biopharmaceutical company founded to develop therapeutic targeted nanoparticles to produce best in class drugs. Initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/bind-biosciences">BIND Biosciences</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>BIND Biosciences (NASDAQ: BIND) is a biopharmaceutical company founded to develop therapeutic targeted nanoparticles to produce best in class drugs. Initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/bind-biosciences">BIND Biosciences</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Blend Therapeutics</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/blend-therapeutics</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:16 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/blend-therapeutics</guid>

					<description><![CDATA[<p>Blend is developing novel cancer therapeutics designed to overcome efficacy barriers for improved targeting of cancer. Blend’s innovative medicines leverage tumor biology to gain therapeutic advantage in unique ways. With their Pentarin platform, they create miniaturized biologic drug conjugate (mBDC) incorporated in polymeric nanoparticles that are designed to reach and penetrate the solid tumor and&#8230;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/blend-therapeutics">Blend Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Blend is developing novel cancer therapeutics designed to overcome efficacy barriers for improved targeting of cancer. Blend’s innovative medicines leverage tumor biology to gain therapeutic advantage in unique ways. With their Pentarin platform, they create miniaturized biologic drug conjugate (mBDC) incorporated in polymeric nanoparticles that are designed to reach and penetrate the solid tumor and then selectively kill the targeted cancer cells. With their novel personalized Platinum, they have designed it to take advantage of the biology of certain solid tumor cancer cells by using the cell’s appetite for albumin to increase uptake, leading to enhanced efficacy response.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/blend-therapeutics">Blend Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>CytrellisBiosystems, Inc.</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/cytrellisbiosystems-inc</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:16 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/cytrellisbiosystems-inc</guid>

					<description><![CDATA[<p>Cytrellis Biosystems Inc. is a clinical stage medical device company developing a new class of medical devices with an unprecedented ability to reverse age related changes in skin and restore youthful beauty. Their products will address a longstanding need to provide doctors and their patients with a safe, effective and non-surgical means to eliminate unwanted&#8230;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/cytrellisbiosystems-inc">CytrellisBiosystems, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Cytrellis Biosystems Inc. is a clinical stage medical device company developing a new class of medical devices with an unprecedented ability to reverse age related changes in skin and restore youthful beauty. Their products will address a longstanding need to provide doctors and their patients with a safe, effective and non-surgical means to eliminate unwanted loose skin and wrinkles – conditions that up until now have been most effectively treated with plastic surgery.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/cytrellisbiosystems-inc">CytrellisBiosystems, Inc.</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Exosome Diagnostics</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/exosome-diagnostics</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:16 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/exosome-diagnostics</guid>

					<description><![CDATA[<p>Exosome Diagnostics, is developing body fluid-based cancer diagnostics using its exosome-based technology for disease stratification and patient response monitoring. Exosome Diagnostics&#8217; technology allows for minimally invasive testing of cancer specific genes from standard blood and urine samples.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/exosome-diagnostics">Exosome Diagnostics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Exosome Diagnostics, is developing body fluid-based cancer diagnostics using its exosome-based technology for disease stratification and patient response monitoring. Exosome Diagnostics&#8217; technology allows for minimally invasive testing of cancer specific genes from standard blood and urine samples.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/exosome-diagnostics">Exosome Diagnostics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
